Coherus Oncology, Inc.

Listed Company

CHRSCIK 0001512762NasdaqAcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$168.02M

Total Assets

$258.34M

Equity

$61.01M

Shares Out

154.25M

Op. Cash Flow

$-138.51M

CHRS$1.40+56.85% · past yearDBEQ Basic

Daily closing prices

Business

Coherus Oncology, Inc. is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), for nasopharyngeal carcinoma, and a pipeline including two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. The company develops and commercializes proprietary immuno-oncology medicines, selling LOQTORZI in the United States and Canada through wholesale distribution channels and pursuing partnerships to combine LOQTORZI with its pipeline candidates. Coherus operates as a single reportable segment focused on oncology drug development and commercialization with U.S.-based manufacturing initiatives.

Summary from 10-K filed 2026-03-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue	42	26	257	211	327
Cost of goods sold	14	9	159	70	58
Research and development	109	92	109	199	363
Selling, general and administrative	101	125	192	198	170
Total costs and expenses	223	226	460	468	590
Loss from operations	−181	−200	−203	−257	−264
Interest expense	−9	−11	−41	−32	−23
Loss on debt extinguishment	0	−13	—	−6	—
Other income (expense), net	7	8	5	4	−283,000
Loss from continuing operations before income taxes	−183	−215	−238	−292	−287
Income tax provision	0	0	−380,000	0	0
Net loss from continuing operations	−183	−215	—	—	—
Net income from discontinued operations, net of tax (Note 6)	351	244	—	—	—
Net income	168	29	−238	−292	−287
Net loss from continuing operations - basic	−1.56	−1.88	—	—	—
Net loss from continuing operations - diluted	−1.56	−1.88	—	—	—
Net income from discontinued operations - basic	3	2.13	—	—	—
Net income from discontinued operations - diluted	3	2.13	—	—	—
Net income per share - Basic (In dollar per share)	1.43	0.25	−2.53	−3.76	−3.81
Net income per share - Diluted (In dollar per share)	1.43	0.25	−2.53	−3.76	−3.81
Basic (In shares)	117	115	94	78	75
Diluted (In shares)	117	115	94	78	75

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	89	126	103	64	417
Investments in marketable securities	83	—	15	128	—
Trade receivables, net	18	111	261	110	123
TSA receivables, net	603,000	11	—	—	—
Inventory	3	4	63	39	38
Prepaid manufacturing	7	7	24	18	14
Other prepaids and current assets	6	10	11	23	11
Assets of discontinued operations, current (Note 6)	—	72	—	—	—
Total current assets	207	342	476	381	602
Property and equipment, net	1	3	5	9	8
Inventory, non-current	0	0	67	76	56
Intangible assets, net	46	54	72	—	—
Other assets, non-current	4	6	10	9	10
Assets of discontinued operations, non-current (Note 6)	—	44	—	—	—
Total assets	258	449	630	481	679
Accounts payable	10	28	35	12	16
Accrued rebates, fees and reserves	30	165	170	54	79
TSA payables and accrued liabilities	65	11	—	—	—
Accrued compensation	15	18	22	23	22
Accrued and other current liabilities	20	60	105	50	48
Total current liabilities	140	283	332	139	165
Term loan, non-current	37	37	246	245	76
Convertible notes, non-current	—	228	227	226	333
Lease liabilities, non-current	1	3	5	5	7
Other liabilities, non-current	18	29	13	3	750,000
Total liabilities	197	581	823	618	582
Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 121,154,925 and 115,614,548 at December 31, 2025 and December 31, 2024, respectively)	12,000	12,000	11,000	8,000	7,000
Additional paid-in capital	1,444	1,419	1,386	1,204	1,148
Accumulated other comprehensive loss	−195,000	−275,000	−248,000	−249,000	−270,000
Accumulated deficit	−1,383	−1,551	−1,580	−1,342	−1,050
Total stockholders' equity (deficit)	61	−132	−193	−137	98
Total liabilities and stockholders' equity (deficit)	258	449	630	481	679

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	4	5	4	4	3
Stock-based compensation expense	17	28	43	51	51
Write-down of intangible assets and remeasurement of contingent consideration liabilities, net	4	7	—	—	—
Loss on debt extinguishment	10	13	—	—	—
Gain on Sale Transactions, net (Note 6)	−338	−177	—	—	—
Inventory write-downs, net	—	14	53	26	5
Change in fair value of derivatives	13	5	375,000	—	—
Other non-cash adjustments, net	−10	82,000	−5	−705,000	588,000
Trade receivables, net	94	149	−151	13	34
Inventory	−17	−32	−47	−47	−6
Prepaid manufacturing	338,000	5	2	−4	4
Other prepaid, current and non-current assets	5	−838,000	16	−13	−5
Accounts payable	−20	−4	24	−5	874,000
Accrued rebates, fees and reserves	−119	−6	113	−25	−3
TSA related operating assets and liabilities, net	64	—	—	—	—
Accrued compensation	−4	2	−5	596,000	−230,000
Accrued and other current and non-current liabilities	−9	−57	11	1	18
Net cash used in operating activities	−139	−20	−175	−241	−37
Purchases of investments in marketable securities	−104	—	−20	−127	−182
Proceeds from maturities of investments in marketable securities	21	6	144	—	100
Proceeds from sale of investments in marketable securities	—	9	13	—	82
Net cash received related to the Sale Transactions (Note 6)	470	228	—	—	—
Milestone payments to Junshi Biosciences	−13	−13	—	−35	—
Other investing activities, net	−342,000	110,000	−492,000	−4	—
Net cash provided by investing activities	375	230	145	−167	−138
Proceeds from (repayment of) Revenue Purchase and Sale Agreement, net of issuance costs	−48	36	—	—	—
Proceeds from issuance of common stock under Private Placement, net of issuance costs	8	—	—	—	—
Proceeds from issuance of common stock under Sales Agreement, net of issuance costs	—	1	—	—	41
Proceeds from purchase under the employee stock purchase plan	353,000	926,000	2	2	3
Taxes paid related to net share settlement	−283,000	−2	−4	−4	−2
Redemption of 2026 Convertible Notes, including transaction costs	−233	—	—	−109	—
Repayment of 2027 Term Loans, premiums and make-whole	—	−260	—	−82	—
Other financing activities, net	−832,000	43,000	−1	−1	−672,000
Net cash used in financing activities	−274	−187	70	54	52
Net increase (decrease) in cash, cash equivalents and restricted cash	−37	23	39	−354	−124
Cash paid for interest	10	25	38	35	19
Income taxes paid (refunded), net	36,000	−114,000	−118,000	40,000	1
Non-cash employee bonuses settled in common stock	—	4	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Coherus Oncology, Inc.'s CIK number?

Coherus Oncology, Inc.'s SEC CIK number is 0001512762 (1512762). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Coherus Oncology, Inc.'s SEC filings?

All of Coherus Oncology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Coherus Oncology, Inc. last report earnings?

Coherus Oncology, Inc. (CHRS) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-058666). This is Coherus Oncology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Coherus Oncology, Inc.'s most recent earnings 8-K?

Coherus Oncology, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001104659-26-058666. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Coherus Oncology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →